title: Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis.
abstract: OBJECTIVE
  Data on the influence of acetaminophen intake on acute viral hepatitis is scarce, but it could play a role in the worsening of this disease. The aim of this study was to determine whether the intake of acetaminophen at therapeutic doses affects the severity of acute viral hepatitis.
  
  
  METHODS
  This was a prospective study concerning 37 consecutive patients hospitalized for acute viral hepatitis. Acetaminophen consumption and time since last intake were assessed by a questionnaire. Parameters of severity were studied in comparison to time related serum concentrations of acetaminophen.
  
  
  RESULTS
  Patients hospitalized for acute viral hepatitis (18 male, 19 female patients) had a mean age of 29.2 +/- 11.5 years. The causal virus was HAV (n=23), HBV (n=7) and other viruses (n=8). The mean cumulated dose of acetaminophen was 7.7 +/- 5.65 g. The daily dose did not exceed the therapeutic dosage and the mean was 1.95 +/- 0.81 g (1-3 g). Patients who received 7.5 g of acetaminophen or more had a lower prothrombin index 52.4 +/- 30.3% vs 74.2 +/- 17.2% (P=0.039), and a lower factor V 54.7 +/- 33.2% vs 83.3 +/- 19.6% (P=0.033). Prothrombin index and bilirubinemia were negatively correlated with time related plasma acetaminophen concentrations.
  
  
  CONCLUSIONS
  The use of acetaminophen at therapeutic doses was associated with greater alterations of surrogate markers of the severity of acute viral hepatitis especially hepatitis A. This was related to cumulated dosages and correlated to the time related acetaminophen plasma concentrations. Acetaminophen use should be interrupted when acute hepatitis is suspected.
authors.affiliation: Division of Gastroenterology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon. cesar.yaghi@usj.edu.lb
authors.forename: César
authors.initials: C
authors.lastname: Yaghi
authors.forename: Khalil
authors.initials: K
authors.lastname: Honein
authors.forename: Joseph
authors.initials: J
authors.lastname: Boujaoude
authors.forename: Rita
authors.initials: R
authors.lastname: Slim
authors.forename: Rami
authors.initials: R
authors.lastname: Moucari
authors.forename: Raymond
authors.initials: R
authors.lastname: Sayegh
mesh_terms: D000082:Acetaminophen / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001663:Bilirubin / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D005260:Female; D006525:Hepatitis, Viral, Human / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011517:Prothrombin Time; D012720:Severity of Illness Index
chemical_list: D018712:Analgesics, Non-Narcotic; D015415:Biomarkers; D000082:Acetaminophen; D001663:Bilirubin